



## Treatment of Alzheimer Disease

Guest Editor:

**Dr. Giulia Sita**

Department of Pharmacy and  
Biotechnology, University of  
Bologna, Bologna, Italy

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

Dear Colleagues,

Alzheimer's disease (AD) is the most common neurodegenerative disease that represents the principal cause of dementia worldwide. The social and economic burden behind this disease affects families, caregivers and, obviously, patients. Numerous factors are involved in the onset and progression of AD, but the exact mechanisms leading to the accumulation of  $\beta$ -amyloid (A $\beta$ ) protein and the formation of neurofibrillary tangles of tau protein in the brain are still unresolved. In addition to the effort spent searching for new innovative treatments which are able to stop the progression of AD, to date, all treatments available are only applicable to symptomatic patients. Thus, the identification of modifications that accumulate with aging in the AD brain is certainly needed to discover new successful therapeutic approaches.

In this Special Issue, "Treatment of Alzheimer Disease", we invite investigators to contribute original research articles and review articles regarding the novel therapeutic approaches to counteract AD progression.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)